323990 — Vaxcell Bio Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual cashflow statement for Vaxcell Bio Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-1,254	-3,984	-4,763	-6,825	-10,274
Depreciation
Amortisation
Non-Cash Items	-1,980	560	270	291	-127
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital	-540	-64.6	-427	178	578
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-3,589	-3,303	-4,662	-6,045	-9,423
Capital Expenditures	-903	-31.9	-2,228	-290	-199
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	2,975	-20,017	-1,009	4,624	-51,588
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	2,073	-20,049	-3,237	4,333	-51,787
Financing Cash Flow Items	—	—	-86.8	—	-1,174
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	1,145	29,180	305	-208	69,866
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-372	5,828	-7,594	-1,919	8,657